Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability (Q35969032)

11 August 2017

title

Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability (English)

1 reference

11 August 2017

1 reference

Alaa-Eldin F Nassar

1

1 reference

11 August 2017

Amin M Kamel

series ordinal

2

1 reference

11 August 2017

Caroline Clarimont

series ordinal

3

1 reference

11 August 2017

publication date

1 December 2004

1 reference

11 August 2017

language of work or name

1 reference

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

23

1 reference

11 August 2017

page(s)

1020-1028

1 reference

publication type of scholarly work

11 August 2017

review article

1 reference

Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Accelerating the drug optimization process: identification, structure elucidation, and quantification of in vivo metabolites using stable isotopes with LC/MSn and the chemiluminescent nitrogen detector

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Quantitative structure--activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

An ABC of Drug-Related Problems

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Computer systems for the prediction of toxicity: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Structure-based methods for predicting mutagenicity and carcinogenicity: are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Timing of new black box warnings and withdrawals for prescription medications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadruple time-of-flight mass spectrometry and in-silico prediction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Online Hydrogen-Deuterium Exchange and a Tandem-Quadrupole Time-of-Flight Mass Spectrometer Coupled with Liquid Chromatography for Metabolite Identification in Drug Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Strategies for dealing with metabolite elucidation in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Role of metabolism and pharmacokinetic studies in the discovery of new drugs--present and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

Isoindol-1-one Analogues of 4-(2‘-methoxyphenyl)-1-[2‘-[N-(2‘‘-pyridyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI) as 5-HT1A Receptor Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903280-5

7 January 2021

10.1016/S1359-6446(04)03280-5

Identifiers

DOI

1 reference

11 August 2017

1 reference